The place of GLP-1-based therapy in diabetes management: Differences between DPP-4 inhibitors and GLP-1 receptor agonists

Dara L. Eckerle Mize, Marzieh Salehi

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)307-318
Number of pages12
JournalCurrent Diabetes Reports
Volume13
Issue number3
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Keywords

  • Cardiovascular risk factors
  • DPP-4
  • DPP-4 inhibitors
  • GLP-1
  • GLP-1 receptor agonists
  • Hypoglycemia
  • Incretin
  • Type 2 diabetes
  • Weight loss

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'The place of GLP-1-based therapy in diabetes management: Differences between DPP-4 inhibitors and GLP-1 receptor agonists'. Together they form a unique fingerprint.

  • Cite this